

Trends and Postmarketing Outcomes of Accelerated Approvals (AAs) in FDA New Drug Applications and Biologic License Applications (NDAs/BLAs) from 1992-2025

Sarah Ronnebaum, PhD | HEOR, Precision AQ

Bethesda, MD, USA

For further information, contact sarah.ronnebaum@precisionaq.com or visit us at <https://www.precisionaq.com>

INTRODUCTION

- The United States Food and Drug Administration (FDA) introduced the Accelerated Approval (AA) designation in 1992 to expedite the development and regulatory review of New Drug Applications and Biologic License Applications (NDAs/BLAs).
- AA designation is requested in the drug development process and is intended for treatments that provide a meaningful advantage over available therapies in serious conditions.
- AA designation enables approval based on a surrogate endpoint (i.e., conditional approval) but requires confirmatory trials for conversion to traditional approval (i.e., verified clinical benefit). A conditional approval may be withdrawn if a confirmatory trial is not conducted or if no clinical benefit is observed in the confirmatory trial.
- The objective of this study was to review the features, review time, and regulatory outcomes of NDAs/BLAs approved between 1992-2025 within the FDA Center for Drug Evaluation and Research (CDER).




METHODS

- Trends in AA designations were examined among original NDAs/BLAs within CDER.¹ Applications with multiple indications were considered to have AA if any indication had AA. Relative risks (RR) with 95% confidence intervals (CI) were calculated for comparisons of interest.
- All original and supplemental NDAs/BLAs within CDER with verified clinical benefit, ongoing, or withdrawn status from January 1992-December 2025 were reviewed using FDA data.² The Federal Register was searched for details regarding the initiator and rationale for withdrawn applications.³ Vaccines, blood products, gene/cell therapies, and different formulations or dosing for the same drug-indication pair were excluded from analysis.

RESULTS

Original NDAs/BLAs within CDER:

- Among 1,208 original NDAs/BLAs approved between 1992-2025, 160 had AA designation and received conditional approval (13%). The proportion of conditional approvals generally increased during the timeframe (**Figure 1**).
- Applications with AA were more likely to receive priority review; 95% of applications with AA received priority review, while 46% of applications without AA received priority review (RR [95% CI] = 2.08 [1.93, 2.25]).
- Irrespective of priority or standard review status, applications with AA had shorter mean and median application review time within CDER than applications without AA. AA designation saved a mean (median) of 3.8 (0.5) months for applications under priority review and saved 8.0 (2.8) months for applications under standard review (**Figure 2**).



Original and supplemental NDAs/BLAs that received conditional approval within CDER:

- Across 291 original and supplemental NDAs/BLAs with conditional approval, 60% of approvals have been verified, while 26% are ongoing and 14% have been withdrawn (**Figure 3**).
 - Among verified applications, the mean (median) time from conditional to traditional approval between 1992-2025 was 48.4 months. The time to traditional approval trended longer in the period between 1992-2014 (57.0 [45.9] months) versus 2015-2025 (37.8 [33.6] months; **Figure 4**).
 - For indications that received conditional approval between 2021-2025 and are ongoing, the mean (median) projected time to complete postmarketing requirements is 46.5 (47.4) months.
- Figure 5: Reasons for conditional AA withdrawal**
-
- | Reason | Percentage |
|---|------------|
| Postmarketing trial did not verify clinical benefit | 54% |
| No postmarketing trial was conducted | 27% |
| Safety concerns only | 11% |
| Safety concerns and no benefit | 5% |
| Manufacturer reprioritized resources | 1% |
- Graph represents withdrawn applications with details available in the Federal Register (n = 37). Only three instances were identified in which the manufacturer appealed the FDA's recommendation for voluntary withdrawal.
- Among withdrawn AA indications, key reasons for withdrawal included a lack of clinical benefit (7% of all AAs), no trial being conducted (3%), safety concerns (2%), or resource reallocation (<1%; **Figure 5**).
 - Manufacturers voluntarily withdrew applications in 92% of instances after receiving the FDA's recommendation.

CONCLUSIONS

- The AA program accelerates patient access to therapies that treat serious and life-threatening conditions. More than half of all conditional approvals have converted to traditional approvals, and ongoing conditional approvals are expected to complete requirements within four years. Withdrawals are uncommon, and withdrawals due to safety issues are rare (2% of all conditional approvals).
- The uncertainty regarding clinical benefit of a conditional approval is balanced against the earlier access enabled by AA's use of surrogate endpoints. The reduction in the postmarketing requirement period that has occurred in recent years mitigates this uncertainty.^{4,5} In oncology, both the National Comprehensive Cancer Network (NCCN) guidelines and clinical practice patterns demonstrate rapid awareness of a lack of benefit from confirmatory trials.^{6,7}
- The dramatic increase in survival gains that has been ascribed to the AA program is an essential consideration in evaluations of the value of AA.^{8,9} However, verifying clinical benefit through confirmatory trials is critical to patients and prevents unnecessary spending on therapies that do not enhance survival.^{10,11}

References

- US FDA. Compilation of CDER NME and New Biologic Approvals 1985-2024. Available at <https://www.fda.gov/media/177921/download?attachment>. Accessed Dec 20, 2025.
- US FDA. Accelerated Approval Program. Available at <https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program>. Accessed Jan 2, 2026.
- National Archives. Federal Register. Available at <https://www.federalregister.gov/documents/search>. Accessed Jan 2, 2026.
- Beakes-Read G, et al. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021. *Ther Innov Regul Sci*. 2022 Sep;56(5):698-703.
- Kester R, et al. The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab. *Drugs*. 2024 Dec;84(12):1579-1601.
- Mooghalli M, et al. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. *BMJ Med*. 2024 Apr 5;3(1):e000862.
- Hwang CS, et al. Changes in Oncology Medication Use After Withdrawal of Accelerated Approval. *JAMA Oncol*. 2025 Jun 1;11(6):664-666.
- Benedict A, et al. Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model. *J Natl Compr Canc Netw*. 2024 Apr 22;22(6):382-389.
- Wong W, et al. The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. *Future Oncol*. 2024;20(16):1099-1110.
- Forrest R, et al. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. *Lancet Oncol*. 2024 Dec 1;25(12):1635-43.
- Naoi H, et al. Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. *BMJ Med*. 2025 Dec 16;4(1):e001934.

Funding provided by Precision AQ.